Plant Name: Curcuma kwangsiensis
Taxonomic Information:
Plant ID: NPO22741
Plant Latin Name: Curcuma kwangsiensis
Taxonomy Genus: Curcuma
Taxonomy Family: Zingiberaceae
Plant External Links:
NCBI TaxonomyDB:
136216
Plant-of-the-World-Online:
872373-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| TSHR; NPSR1; | |
| PTGES; ALOX15; | |
| MAPK1; | |
| PPARA; | |
| NR1H4; | |
| MAOA; | |
| TP53; | |
| FABP3; FABP4; LMNA; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP19A1; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 5.446E-09 | 5.929E-05 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.061E-06 | 2.309E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.053E-06 | 2.812E-03 | CYP19A1, FFAR4, NR1H4, PPARA |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 4.479E-06 | 4.861E-03 | ALOX15, FABP4, MAPK1, PTGES, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 6.938E-06 | 6.043E-03 | FABP3, FFAR4, PPARA, TP53, TSHR |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 1.348E-05 | 9.405E-03 | PPARA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.288E-07 | 2.929E-05 | FABP3, FABP4, FABP5, PPARA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.078E-05 | 5.627E-03 | MAOA, ALOX15, MAPK1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.759E-04 | 5.627E-03 | LMNA, MAPK1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.511E-04 | 5.627E-03 | MAPK1, PPARA, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.939E-04 | 9.031E-03 | MAPK1, PPARA, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 2.406E-04 | 6.158E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 4.832E-04 | 9.031E-03 | MAPK1, TP53 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGES; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
